Picture of Cann logo

CAN — Cann News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapTurnaround

Australia's Cann Group hits record low on disappointing clinical trial results

** Shares of Cann Group Ltd  CAN.AX  fall as much as 9.8% to
a record low of A$0.185 
    ** Stock eyes worst day since Oct. 25, 2022, if losses hold 
    ** Medicinal cannabis maker announces phase 3 clinical trial
results for its Satipharm CBD capsule used to treat sleep
disturbances     
    ** Says preliminary view of analysis for primary end-points
have not shown a statistically superior response 
    ** Co expects trial results to delay submission of the
registration application to the Therapeutic Goods Administration
(TGA) 
    ** Stock fell 29.3% in 2022 
 (Reporting by Nausheen Thusoo in Bengaluru)
 ((Nausheen.Thusoo@thomsonreuters.com;))

Recent news on Cann

See all news